Ycg Raised Its Position in Nike (NKE) by $3.67 Million as Market Valuation Rose; Palo Alto Investors Cut Its Amicus Therapeutics (FOLD) Stake by $19.80 Million; Valuation Rose

May 21, 2018 - By Michael Collier

NIKE, Inc. (NYSE:NKE) Logo

Ycg Llc increased its stake in Nike Inc (NKE) by 17.93% based on its latest 2017Q4 regulatory filing with the SEC. Ycg Llc bought 59,271 shares as the company’s stock rose 4.55% while stock markets declined. The institutional investor held 389,806 shares of the consumer non-durables company at the end of 2017Q4, valued at $24.49M, up from 330,535 at the end of the previous reported quarter. Ycg Llc who had been investing in Nike Inc for a number of months, seems to be bullish on the $115.13B market cap company. The stock increased 0.15% or $0.11 during the last trading session, reaching $71.43. About 4.13M shares traded. NIKE, Inc. (NYSE:NKE) has risen 18.31% since May 21, 2017 and is uptrending. It has outperformed by 6.76% the S&P500.

William Leland Edwards decreased its stake in Amicus Therapeutics Inc (FOLD) by 19.06% based on its latest 2017Q4 regulatory filing with the SEC. Palo Alto Investors Llc sold 1.41 million shares as the company’s stock rose 0.85% while stock markets declined. The hedge fund run by William Leland Edwards held 6.01M shares of the health care company at the end of 2017Q4, valued at $86.43 million, down from 7.42 million at the end of the previous reported quarter. Palo Alto Investors Llc who had been investing in Amicus Therapeutics Inc for a number of months, seems to be less bullish one the $2.96 billion market cap company. The stock decreased 6.09% or $1.02 during the last trading session, reaching $15.72. About 2.30 million shares traded. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 90.40% since May 21, 2017 and is uptrending. It has outperformed by 78.85% the S&P500.

Investors sentiment decreased to 0.74 in 2017 Q4. Its down 0.06, from 0.8 in 2017Q3. It turned negative, as 70 investors sold NKE shares while 501 reduced holdings. 109 funds opened positions while 312 raised stakes. 1.01 billion shares or 2.95% more from 985.62 million shares in 2017Q3 were reported. 1,032 are held by Qci Asset Mngmt Ny. Mairs Pwr accumulated 4,400 shares. The New York-based Gamco Invsts Et Al has invested 0.01% in NIKE, Inc. (NYSE:NKE). Waddell Reed Financial Inc reported 0.03% of its portfolio in NIKE, Inc. (NYSE:NKE). Moreover, Gulf Financial Bank (Uk) Ltd has 0.33% invested in NIKE, Inc. (NYSE:NKE). Moreover, Autus Asset Mgmt Limited Liability Company has 1.52% invested in NIKE, Inc. (NYSE:NKE). Fukoku Mutual Life Insur Co owns 4,700 shares. Court Place Advsrs Limited Liability reported 12,927 shares. Stephens Ar reported 95,519 shares stake. Thompson Siegel & Walmsley reported 5,528 shares. Cim Investment Mangement invested 0.23% of its portfolio in NIKE, Inc. (NYSE:NKE). Huntington Steele Limited Company holds 0.13% or 7,956 shares. Motco invested 0.59% of its portfolio in NIKE, Inc. (NYSE:NKE). Duncker Streett & invested in 38,300 shares or 0.62% of the stock. Fiera stated it has 1.52% of its portfolio in NIKE, Inc. (NYSE:NKE).

Since December 11, 2017, it had 0 insider purchases, and 8 insider sales for $45.81 million activity. 100,000 shares were sold by EDWARDS TREVOR A, worth $6.85M. On Friday, January 5 the insider Slusher John F sold $4.75 million. SPRUNK ERIC D sold 100,000 shares worth $6.77M. Matheson Monique S. had sold 10,000 shares worth $620,000 on Monday, December 11.

More notable recent NIKE, Inc. (NYSE:NKE) news were published by: Bizjournals.com which released: “Nike leadership shuffle continues with new leaders for women’s, running categories” on May 08, 2018, also Bizjournals.com with their article: “Exclusive: Nike promotes second senior female manager in continued leadership shakeup” published on April 28, 2018, Bizjournals.com published: “A former Nike executive launches Portland’s first luxury women’s sportswear company” on May 09, 2018. More interesting news about NIKE, Inc. (NYSE:NKE) were released by: Bizjournals.com and their article: “Michael Jordan, Nike to steer jersey sale proceeds toward Portland nonprofit” published on May 17, 2018 as well as Seekingalpha.com‘s news article titled: “Nike breaks to new all-time high” with publication date: May 16, 2018.

Among 44 analysts covering Nike Inc. (NYSE:NKE), 26 have Buy rating, 2 Sell and 16 Hold. Therefore 59% are positive. Nike Inc. had 235 analyst reports since July 29, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Thursday, January 11 by Cowen & Co. Piper Jaffray maintained NIKE, Inc. (NYSE:NKE) on Friday, July 21 with “Hold” rating. The firm earned “Buy” rating on Friday, September 25 by Stifel Nicolaus. Canaccord Genuity maintained the shares of NKE in report on Thursday, March 23 with “Hold” rating. The rating was upgraded by Argus Research to “Buy” on Thursday, December 14. On Wednesday, September 28 the stock rating was maintained by FBR Capital with “Mkt Perform”. Bank of America downgraded the stock to “Underperform” rating in Monday, October 31 report. As per Monday, December 28, the company rating was maintained by DA Davidson. B. Riley & Co maintained NIKE, Inc. (NYSE:NKE) rating on Friday, October 16. B. Riley & Co has “Buy” rating and $140 target. The rating was maintained by Canaccord Genuity on Friday, September 25 with “Hold”.

Ycg Llc, which manages about $279.00M and $409.10M US Long portfolio, decreased its stake in Schwab Charles Corp New (NYSE:SCHW) by 7,417 shares to 381,208 shares, valued at $19.59 million in 2017Q4, according to the filing. It also reduced its holding in Mastercard Inc (NYSE:MA) by 4,804 shares in the quarter, leaving it with 201,903 shares, and cut its stake in Express Scripts Hldg Co (NASDAQ:ESRX).

Palo Alto Investors Llc, which manages about $1.30 billion and $2.32 billion US Long portfolio, upped its stake in Immunomedics Inc (NASDAQ:IMMU) by 1.76M shares to 4.77M shares, valued at $77.15M in 2017Q4, according to the filing. It also increased its holding in Epizyme Inc (NASDAQ:EPZM) by 462,547 shares in the quarter, for a total of 6.86 million shares, and has risen its stake in Clovis Oncology Inc (NASDAQ:CLVS).

Analysts await Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report earnings on August, 6. They expect $-0.33 EPS, up 2.94% or $0.01 from last year’s $-0.34 per share. After $-0.28 actual EPS reported by Amicus Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 17.86% negative EPS growth.

Investors sentiment decreased to 1.21 in Q4 2017. Its down 1.12, from 2.33 in 2017Q3. It turned negative, as 25 investors sold FOLD shares while 48 reduced holdings. 25 funds opened positions while 63 raised stakes. 197.59 million shares or 2.54% more from 192.70 million shares in 2017Q3 were reported. Natixis holds 36,911 shares or 0% of its portfolio. Farallon Cap Mngmt Ltd Liability owns 0.33% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 2.78 million shares. Moreover, Prelude Capital Mngmt Ltd Co has 0.06% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 48,848 shares. Jgp Gestao De Recursos Ltda reported 34,149 shares stake. 89,673 were accumulated by Parallax Volatility Advisers Limited Partnership. Aperio Grp Ltd Liability Corp stated it has 15,673 shares or 0% of all its holdings. Jane Street Ltd Limited Liability Company holds 57,455 shares or 0% of its portfolio. Rockefeller Fincl owns 19,169 shares. Maryland-based Proshare Advsr Limited Liability Co has invested 0.01% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). 2,500 were reported by Cubist Systematic Strategies Limited Liability Company. Neuberger Berman Gp Ltd Com owns 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 66,000 shares. Wellington Management Grp Ltd Liability Partnership reported 5.53M shares stake. Deutsche Financial Bank Ag reported 0.02% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Pnc Finance Serv Gp owns 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 128,498 shares. Art Advsrs Ltd Liability owns 44,000 shares or 0.03% of their US portfolio.

NIKE, Inc. (NYSE:NKE) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>